Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine.
The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year.
“We have been collaborating with Merck on PCVs since 2016, and together we have made significant progress in advancing mRNA-4157 as an investigational personalised cancer treatment used in combination with KEYTRUDA,” said Stephen Hoge, President of Moderna.
“With data expected this quarter on PCV, we continue to be excited about the future and the impact mRNA can have as a new treatment paradigm in the management of cancer.”
Under the agreement, Merck will pay Moderna $250 million to exercise its option for personalised cancer vaccines including mRNA-4157/V940 and will collaborate on development and commercialisation. Merck and Moderna will share costs and any profits equally under this worldwide collaboration.
“This long-term collaboration combining Merck’s expertise in immuno-oncology with Moderna’s pioneering mRNA technology has yielded a novel tailored vaccine approach,” said Dr Eliav Barr, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, Merck Research Laboratories.
“We look forward to working with our colleagues at Moderna to advance mRNA-4157/V940 in combination with KEYTRUDA as it aligns with our strategy to impact early-stage disease.”
